Prise en charge de l’asthme léger en 2019–2020 :: que penser des nouvelles propositions thérapeutiques internationales (GINA 2019) ?

Autor: Pierre-Olivier Girodet, Gilles Devouassoux, Antoine Deschildre, Alain Didier, Mathieu Molimard, Cécile Chenivesse, Chantal Raherison, Camille Taillé, Gilles Garcia

Publikováno v: Revue des Maladies Respiratoires
Revue des Maladies Respiratoires, 2020, 37 (5), pp.427-432. ⟨10.1016/j.rmr.2020.03.005⟩
Revue des Maladies Respiratoires, Elsevier Masson, A paraître, 37 (5), pp.427-432. ⟨10.1016/j.rmr.2020.03.005⟩

International audience

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e6a3f632074a6e816243111d2dfaa2f
https://ut3-toulouseinp.hal.science/hal-03565604

Treatment of advanced HR+/HER2- breast cancer with new targeted agents in combination with endocrine therapy: a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib

Autor: Søren Cold, Anders Bonde Jensen, Tea M Bøttcher

Publikováno v: Bøttcher, T M, Cold, S & Jensen, A B 2019, ' Treatment of advanced HR+/HER2− breast cancer with new targeted agents in combination with endocrine therapy : a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib ', Acta Oncologica, vol. 58, no. 2, pp. 147-153 . https://doi.org/10.1080/0284186X.2018.1532603
Bøttcher, T M, Cold, S & Jensen, A B 2019, ' Treatment of advanced HR+/HER2-breast cancer with new targeted agents in combination with endocrine therapy: a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib ', Acta Oncologica, vol. 58, no. 2, pp. 147-153 . https://doi.org/10.1080/0284186X.2018.1532603

Introduction: Recently, new targeted agents have been developed, which can prolong the effect of endocrine treatment (ET) by targeting resistance pathways in HR+/HER2− advanced breast cancer. This review examines available studies of everolimus, an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::daa0942932052480a705d1f354fa46e9
https://pubmed.ncbi.nlm.nih.gov/30375908

Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial?

Autor: Carmen Ochoa, Pedro Berraondo, Alfonso Gurpide, Ignacio Melero, Jose A Melero, Ivan Martinez-Forero, Bruno Sangro, Sandra Hervas-Stubbs, Natalia Suarez, Carlos Alfaro, Jose Luis Perez-Gracia

Publikováno v: Immunotherapy. 1(5)

Stimulating the innate and adaptive immunity against cancer necessitates the tricking of a system evolved to fight microbial pathogens and directing its activity towards transformed self-tissue. Efficacious interventions to start and sustain the resp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::525629dc76c463b536181648b6d8d3a4
https://pubmed.ncbi.nlm.nih.gov/20636027